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ABSTRACT
Introduction: Moisturizers play a prominent
role in the management of atopic dermatitis by
improving the impaired skin barrier function
and enhancing skin hydration. Their efficacy
was evaluated in a recently published Cochrane
Review ‘Emollients and moisturizers for
eczema’.
Objective: In the present review, we summarize
the performance and safety of Cetaphil and
Excipial moisturizing products.
Methods: This review was carried out in com-
pliance with standard Cochrane methodologi-
cal procedures, which means independent
study selection, data extraction, assessment of
risk of bias, and analyses by two review
authors. The quality of evidence for the pre-
defined outcomes was rated with the GRADE
approach. The prespecified outcomes of the
review included participant assessments, satis-
faction, adverse events, investigator assess-
ments, prevention of flares, change in use of
topical active treatment, skin barrier function
and quality of life.
Results: Four randomized controlled studies
examining these moisturizers were included in
the previously published Cochrane Review. For
the performance and tolerability of these
moisturizers, there was very low to moderate
quality evidence for the prespecified outcomes.
Conclusion: The results from these four studies
are in line with those of the Cochrane Review
that moisturizers themselves have beneficial
effects, and that combining moisturizers with
active topical treatment produced better results
when compared to active topical treatment
alone.
Keywords: Atopic dermatitis; Evidence-based
dermatology; GRADE approach; Moisturizers
INTRODUCTION
Atopic dermatitis, also known as atopic eczema
or just eczema, is a chronic inflammatory skin
disease that is characterized by decreased skin
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barrier function, (very) dry skin and inflamma-
tory lesions which cause intense itch leading to
scratching [1]. The etiology of atopic dermatitis
continues to attract research interest, and,
although it is not yet fully understood, most
probably it has a multifactorial origin (e.g.,
genetic, environmental and immunological)
[2]. In the absence of specific laboratory or his-
tological findings [3], the diagnosis of atopic
dermatitis is based on clinical signs and symp-
toms, by using, e.g., the criteria of Hanifin and
Rajka or the UK Working Party’s diagnostic
criteria for atopic dermatitis [4, 5]. Atopic der-
matitis has a lifetime prevalence of 10–20% in
developed countries [3]. The prevalence rates in
developing countries are more difficult to esti-
mate due to the use of different outcome mea-
sures and diagnostic criteria but seem to
increase in certain parts of Africa and eastern
Asia [6]. Since 60% of the diagnoses are made in
the 1st year of life and 85% before age 5,
prevalence is highest in children [3, 7]. A recent
meta-analysis showed that 80% of children with
the disease have outgrown it within 8 years of
onset and this percentage reaches 95% at
20 years after onset [8]. This meta-analysis also
reported that the risk factors for persistence of
the disease are twofold: late-onset and greater
disease severity. The severity of the disease can
vary quite markedly, with data indicating that
80% of affected children have a mild form, and
20% a moderate to severe form [8]. Atopic der-
matitis is further characterized by intermittent
periods of milder symptoms, which are inter-
spersed with sudden relapses or flare-ups (exac-
erbations) [3].
Treatment of atopic dermatitis consists of
the avoidance of triggers that may exacerbate
the disease (e.g., allergens, irritants), of restor-
ing skin barrier function with moisturizers and
by decreasing inflammation through the use of
topical corticosteroids or topical immunomod-
ulators [9]. In more severe cases, systemic
treatment with immunomodulators or pho-
totherapy might have to be considered [9]. The
characteristic flare-ups which can occur in ato-
pic dermatitis make the prevention of flares and
exacerbations one of the key aims of long-term
control [1].
Impaired Skin Barrier
The impairment of the skin barrier in atopic
skin, both lesional and non-lesional, continues
to be a topic of interest [10–17]. The two
mechanisms for this impairment are discussed
further here. Dysfunction of the corneocytes in
the stratum corneum results in a decrease in
production of the protein filaggrin. Filaggrin
itself is broken down into amino acids (e.g.,
arginine) and smaller molecules such as urea,
organic acids (e.g., lactic acid), sugars and elec-
trolytes, which together form the natural
moisturizing factor (NMF) [10, 12, 13]. NMF is
the skin’s natural humectant and is essential for
keeping the stratum corneum properly hydra-
ted, which is necessary for all the biochemical
processes that take place in the skin [10]. The
lamellar bodies within the epithelial cells of the
skin deliver other ingredients for the intercel-
lular membrane of the stratum corneum, such
as free fatty acids, cholesterol and ceramides
(50% of the total lipid weight concerns cer-
amides) [10, 13, 14]. In people with atopic der-
matitis, this production is dysregulated, causing
a different composition of the various cer-
amides and a lack of, e.g., ceramide-1 and cer-
amide-3, which in turn leads to an increase in
transepidermal water loss (TEWL) [10, 11]. In
view of this impairment of skin barrier function,
moisturizing of the skin is considered an
essential part of the treatment regimen for
people with atopic dermatitis [1]. There is thus a
rationality to use moisturizers with ingredients
that mimic the composition of the intercellular
membrane by using, for instance, humectants,
emollients and lipids, or other lacking sub-
stances, and to use occlusives to reduce or fur-
ther prevent TEWL.
Efficacy of Moisturizers
Most studies evaluating the efficacy of mois-
turizers on dry skin or the improvement of skin
disorders have an open label design and often
don’t include a control group. Studies assessing
moisturizers cannot be fairly compared with
studies conducted to demonstrate the efficacy
and safety of drugs, for which methodologically
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robust and randomized controlled trials are
required to obtain approval by the drug regis-
tration authorities (e.g., Food and Drug
Administration or European Medicines
Agency). Moisturizers are most often sold over
the counter without prescription, and therefore
the development of these moisturizers tends to
focus more on tolerance and status of skin
condition (young or old skin, dry skin, sensitive
skin or inflamed skin), rather than on
improvement of atopic dermatitis per se as a
stand-alone treatment. The consequences are,
as has been reported in a meta-analysis on
moisturizers in atopic dermatitis and related
skin disorders, that studies evaluating the effi-
cacy of moisturizers often do not meet the high
standards with regards to methodology, e.g., of
appropriate study size, adequately randomized
and blinded, and using standardized outcome
measures [18]. The efficacy and safety of emol-
lients and moisturizers in atopic dermatitis has
recently been evaluated in a Cochrane Review
titled ‘Emollients and moisturizers for eczema’
[19]. This review reported that ample use of
moisturizers reduces the rate of flares, prolongs
the time to flare and enhances the efficacy of
topical active treatment. This current review
focuses on three of the moisturizers evaluated:
Cetaphil Moisturizing Cream (CMC), Ceta-
phil RestoraDermMoisturizer (CRM) and
Excipial U lipo lotion (EUL). These products,
contain certain ingredients that may restore
barrier function albeit each in a different way,
such as humectants, lipids and/or ceramides (or
their precursors). Four randomized controlled
studies which evaluated these products were
included in the Cochrane Review [20–23].
METHODS
The protocol and subsequent review on which
this sub-analysis is based, were previously pub-
lished in the Cochrane Library [19, 24]. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors. The following databases were searched
up to December 2015: the Cochrane Skin Group
Specialized Register, CENTRAL (2015, Issue 11),
MEDLINE (from 1946), EMBASE (from 1974),
LILACS (from 1982), GREAT database, five
ongoing trials registers (ISRCTN, ClinicalTri-
als.gov, the Australian New Zealand Clinical
Trial Registry, WHO International Clinical Tri-
als Registry and the EU Clinical Trials Register)
and references of the included studies (see, for
search strategy of MEDLINE Appendix 1, Elec-
tronic Supplemental material). Only random-
ized controlled trials (RCT) evaluating the
efficacy and safety of moisturizers in people
with atopic dermatitis, eczema, or atopic
eczema were eligible for inclusion. Two
reviewers (E.J.v.Z. and Z.F.) independently
reviewed all studies from the searches. This
manuscript provides a more in-depth evalua-
tion of the specific RCTs which addressed CMC,
CRM and EUL moisturizers.
Outcome Measures
Our primary outcome measures were (1) par-
ticipant-assessed change in disease severity, (2)
participant’s satisfaction with the moisturizer
and (3) the proportion of participants with an
adverse event. Secondary outcome measures
were investigator-assessed change in disease
severity, prevention of flares, change in use of
active topical treatment, changes in epidermal
barrier function and change in quality of life.
Data Extraction and Synthesis
Trial details of eligible studies were extracted
independently by two review authors using
pre-piloted data extraction forms (E.J.v.Z. and
Z.F.). The risk of bias assessments were made
using the Cochrane domain-based evaluation
tool as described in Chapter 8, Sect. 8.5, in the
Cochrane Handbook for Systematic Reviews of
Interventions [25]. Mean differences (MD) were
calculated for continuous outcomes and for
dichotomous data we calculated risk ratios (RR).
All outcomes were reported with their associ-
ated 95% confidence intervals (CI). We used the
I2 statistic in meta-analyses to assess hetero-
geneity [25]. The quality (or certainty) of the
evidence for the prespecified outcomes was
rated using the GRADE approach [26]. Further
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details on the data analysis are reported in the
full Cochrane Systematic Review [19].
RESULTS
Full details of the process of study selection are
provided in Fig. 1. Four studies which examined
a total of 296 adult patients were included
(Table 1). Two studies [20, 23] were assessed as
at unclear risk of bias, and two studies [21, 22]
as at high risk of bias. Lack of blinding of the
patients was the principal reason that the
studies were judged as high risk of bias (Fig. 2).
In the study of Gehring and Gloor, EUL
containing 4% urea twice daily was compared
to hydrocortisone acetate 1% in EUL in 69
participants over a period of 1 week [20]. Dis-
ease severity was assessed by the participants as
roughness of the skin on a visual analogue scale
(VAS) from 1 to 10, with higher being better.
VAS scores increased from baseline after 1 week
by 2.19 [1.31 standard deviation (SD)] in the 31
patients treated with EUL and 2.60 (0.98 SD) in
the 32 patients that applied hydrocortisone
acetate 1% in EUL with a MD of -0.41 (95% CI
-0.98 to 0.16; P = 0.16). Our primary outcomes
participant satisfaction and adverse events were
not evaluated. Investigators assessed redness on
a 1–4 scale (lower score being less red). The
changes in redness after 1 week were -0.84
(0.66 SD) in the EUL group and -1.00 (0.52 SD)
through other sources 
31 ongoing trials 
database searching 
removed 
5631 records screened 
eligibility 
criteria in Cochrane review 
5471 excluded based on 
47 studies appeared to be 
same study 
with reasons: 
-Controlled clinical trial (2) 
(3) 
31 ongoing studies   




Fig. 1 Flow diagram
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in the hydrocortisone acetate 1% in EUL group
(MD 0.16, 95% CI -0.13 to 0.45; P = 0.29).
Roughness was also assessed on a scale from 1 to
4 and showed changes of -0.97 (0.59 SD) and
-1.06 (0.45 SD), respectively, with a MD of 0.09
(95% CI -0.18 to 0.36; P = 0.52). The other
secondary outcomes were not assessed. The
quality of the evidence was low to moderate for
the addressed outcomes (see Table 2).
A study by Simpson et al. had a within par-
ticipant design in which CRM twice daily was
compared to ‘no moisturizer’ on the contralat-
eral leg of 20 patients over a period of 27 days
[23]. Two of our primary outcomes, disease
severity as assessed by the participants and their
satisfaction with the moisturizer, were not
evaluated. Adverse events were evaluated and
there were none reported to the treatment. In
this study, the investigators used a dryness scale
(0–4, higher score being worse) to assess disease
severity. The reductions reported at the end of
27 days were 1.15 (0.41 SD) on the legs of the 20
patients treated with CRM and 0.91 (0.58 SD)
on the non-treated contralateral legs with a
mean of the paired differences of -0.24 (95% CI
-0.42 to -0.06). In addition, both TEWL
(measured with an evaporimeter) and skin
hydration (measured with a corneometer) were
used to investigate changes in skin barrier
function. The reduction in TEWL was 1.59 g/
m2/h (0.97 SD) on the CRM treated legs and
0.42 g/m2/h (1.13 SD) on the contralateral legs
with a mean of the paired differences of
-1.17 g/m2/h (95% CI -1.52 to -0.82). How-
ever, both of these reductions can be regarded
as relatively minimal. Skin hydration improved
by 16.91 units (6.31 SD) on the CRM treated
legs and by 3.3 (3.86 SD) on the non-treated
Fig. 2 Risk of bias summary
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contralateral legs (mean of the paired differ-
ences 13.61, 95% CI 11.60–15.60). There was a
statistically significant difference in favor of
CRM for all of these specific investiga-
tor-assessed outcomes. None of the other sec-
ondary outcomes (prevention of flares, change
in active topical treatment and quality of life)
were assessed in this study. The quality of the
evidence was rated low to very low for the pre-
specified outcomes that were addressed (see
Table 3).
The two studies at high risk of bias (due to
lack of blinding of the participants) evaluated
topical corticosteroids plus moisturizer versus
topical corticosteroid alone [21, 22].
In Hanifin et al. desonide 0.05% lotion twice
daily in combination with the use of moistur-
izing cream three times daily (CMC) was com-
pared over a period of 3 weeks to desonide
0.05% lotion twice daily, in 80 participants in a
within-participant study design [21]. In the
within-participant design study of Simpson
et al., routine use of topical corticosteroids
combined with twice daily CRM was compared
to routine use of topical corticosteroids alone
without the use of any moisturizer [22]. This
study examined these comparisons in 123
patients over a 4-week period [22]. Partici-
pant-assessed disease severity was not assessed
in either of the two studies. However, although
participant satisfaction was measured in both, it
did not involve the more direct measurement of
our outcome of ‘satisfaction’. Thus, in Hanifin
et al. [21], it was measured as ‘preference’, and
in Simpson et al. [22] as ‘perception of the
product’. In Hanifin et al. [21], the combined
therapy of desonide 0.05% lotion plus mois-
turizing cream was preferred by 96% of the 78
participants and the remaining 4% preferred the
desonide 0.05% lotion without the use of any
moisturizer. In the other study [22], between
84.3% and 96.7% of the 123 participants
reported that adding CRM to topical corticos-
teroids ‘‘reduces inflammation, relieves dry and
itchy skin, provides long-lasting hydration,
leaves skin protected and maintains healthy
skin’’ [22]. Adverse events were only reported in
one of the two studies [21]. After the 1st week of
the study, 10 of the 80 participants reported
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desonide 0.05% and moisturizer, compared to
11 reports on the side treated with desonide
0.05% lotion alone. However, after 3 weeks, no
adverse events were reported for the combined
treatment, but two participants still reported
burning and stinging on the side treated with
desonide 0.05% lotion alone [21].
The investigators in Hanifin et al. assessed
disease severity as ‘global assessment of
improvement’ [21]. Based on a per-protocol
analysis of 78 participants and their assessments,
70% of the participants were markedly improved
to ‘clear’ on the body side treated with desonide
0.05% lotion with moisturizer used three times a
day, versus 55% on the side that was treated with
only desonide 0.05% lotion (investigators
reported a P value of\0.01).
The investigators in Simpson et al. used the
Eczema Area and Severity Index (EASI; score
0–72, higher is worse) [22]. The reductions in
EASI were small on both sides and did not meet
the minimal important difference (MID) of 6.6
[27]. On the side treated with desonide 0.05%
lotion and moisturizer the reduction was 1.28
(1.94 SD) and on the desonide 0.05% lotion
‘only’ treated side 1.0 (1.50 SD), with a mean of
the paired differences of -0.27 (95% CI -0.52
to -0.02), which although statistically signifi-
cant is not clinically important.
Only Simpson et al. investigated skin barrier
function using corneometry [22]. On the side
treated with topical corticosteroids combined
with moisturizer, skin hydration increased by
5.4 arbitrary units compared to 3 arbitrary units
on the side treated with topical corticosteroids
alone, both of which were considered small
improvements. The other secondary outcomes
(prevention of flares, change in topical active
treatments and quality of life) were not assessed
in these two studies. The quality of evidence
was rated low to moderate for the addressed
outcomes (see Table 4).
DISCUSSION
The duration of the studies did not last beyond
4 weeks, and three of the four studies addressed
the efficacy of moisturizers combined with
topical corticosteroids in atopic dermatitis
[20–22]. One study was conducted in people
with controlled atopic dermatitis [23]. However,
none of the studies were designed as mainte-
nance studies to evaluate the efficacy of mois-
turizers in preventing flares.
One randomized controlled trial, which was
conducted 20 years ago, evaluated EUL, a
moisturizer containing 4% urea and 36% lipids
[20]. As only the 1st week of this 2-week study
was randomized, we could only include the 1st
week’s data. Based on these data, we can con-
clude that adding hydrocortisone acetate 1% to
the EUL did not make a difference in terms of
efficacy compared to EUL used alone.
Urea is normally present in healthy skin as
part of the natural moisturizing factor (NMF) in
the stratum corneum [14]. Urea is a humectant
with water attracting properties from dermis
into epidermis and aids in holding water in the
stratum corneum [14, 28, 29]. In atopic skin
epidermal barrier function is impaired, TEWL is
increased and the ability to retain water in the
skin is decreased [14, 29]. Urea-containing
moisturizers enhance hydration, but also appear
to improve skin barrier function and antimi-
crobial defense [30]. In concentrations of 10%
and higher, urea works as a keratolytic agent
and therefore urea-containing moisturizers
work well on both dry and scaly skin.
Based on the published Cochrane Review,
there was low to moderate quality evidence for
the effect of urea-containing moisturizers, and
these could reduce the risk of flare by one-third
when compared to the use of no moisturizer or
compared to its vehicle. A long-term study
conducted over a period of 180 days also
demonstrated that urea 5%-containing cream
could, after the atopic dermatitis had been (al-
most) cleared with topical corticosteroids,
reduce the number of patients having a flare
during the 6-months follow-up, as well as
increase the time to flare when compared to a
moisturizer without urea [31]. Over the last
20 years, the urea-containing product line
(which includes EUL) has expanded its devel-
opment to ‘‘hydrate to relieve, protect, and
repair the most dry and frustrating skin’’ [32].
Whereas it is unlikely that many more ran-
domized controlled trials with urea-containing
moisturizers will be conducted, the benefits of
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urea appear to be already well acknowledged by
most physicians as well as patients, even in the
absence of robustly designed and conducted
studies. The most important reasons for down-
grading the quality of the evidence for urea-con-
tainingmoisturizers in theCochrane Reviewwere
low sample sizes, making the effect estimate less
precise (due to wide confidence interval) and risk
of bias (e.g., lack of blinding) [19]. The absence of
high-quality evidence is more directly related to
the poormethodological quality and lownumber
of existing studies than to the efficacy of the
urea-containing moisturizers.
The other three included studies evaluated
CRM and CMC [21–23]. The study of Simpson
et al. demonstrated that CRM performed better
on all assessed outcomes than no moisturizer,
albeit based on very low- to low-quality evi-
dence [23]. This product has been especially
developed for atopic skin, and contains occlu-
sives, emollients and humectants to restore and
maintain barrier function and prevent
transepidermal water loss [10]. Additional
inclusion of NMFs and pseudoceramides among
others within this product have been shown to
be capable of augmenting the water-binding
and -holding properties of the stratum corneum
[10, 13]. The recently published Cochrane
Review emphasized that most moisturizers
showed some beneficial effects; however, the
extent of the benefits varied among the inclu-
ded studies [19]. Nonetheless, it was clear that
the use of moisturizers prolonged time to flare,
reduced the number of flares, and, when mois-
turizers were abundantly and frequently
applied, also reduced the need for topical active
treatment. Another important conclusion of the
Cochrane Review was that there was moder-
ate-quality evidence that adding a moisturizer
to topical active treatment was more effective
than topical active treatment alone [19]. This
was confirmed by two of the studies in this
report which evaluated CRM in combination
with active treatment and CMC [21, 22].
CONCLUSIONS
The four randomized controlled studies included
in this review on EUL, CMC and CRM show that
they have to a certain extent beneficial effects for
their use in atopic dermatitis, including as an
add-on to augment topical active treatment,
although the quality of the evidence was very
low to moderate for the prespecified outcomes.
The conclusions reached in these studies are
in concordance with those drawn in the
Cochrane Review, and essentially reinforce the
rationality and benefits of moisturizer therapy.
Gaps in the evidence included a lack of clarity as
to which moisturizers are preferred for the dif-
ferent parts of the body and any indication of
how personal preferences and external factors
(e.g., weather, seasons) influenced the choice of
moisturizer. Most importantly, there was a
noticeable lack of assessment of the compara-
tive effectiveness of the moisturizers, e.g., as to
which are most appropriate for the actual dis-
ease status (acute or chronic) and severity (mild,
moderate or severe). Therefore, clinical deci-
sion-making on the choice of moisturizer
should be based not only on the available evi-
dence but should also take into account the
experiences and preferences of the individual
suffering from atopic dermatitis, as well as the
direct costs for the patients.
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31. Åkerström U, Reitamo S, Langeland T, Berg M,
Rustad L, Korhonen L. Comparison of moisturizing
creams for the prevention of atopic dermatitis
relapse: a randomized double-blind controlled
multicentre clinical trial. Acta Derm Venereol.
2015;95:587–92.
32. Excipial. http://www.excipial.ca/en. Accessed 19
March 2017.
Dermatol Ther (Heidelb) (2017) 7:331–347 347
